[ NATIONAL · CH ]
Outside the EU single market, inside the European regulatory conversation through mutual recognition.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
EUROPE
The Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA), SR 812.21, of 15 December 2000. It rests on Articles 95 paragraph 1 and 118 paragraph 2 of the Federal Constitution, and Article 1 states its purpose as protecting human and animal health and guaranteeing that only high quality, safe and effective therapeutic products are placed on the market. Article 2 sets the scope: the handling of medicinal products and medical devices, narcotics under the Narcotics Act of 3 October 1951 insofar as they are used as therapeutic products, and therapeutic treatments such as gene therapy where they relate directly to therapeutic products.
Through Swiss federal law administered by Swissmedic — the Swiss Agency for Therapeutic Products — which has been a PIC/S Participating Authority since February 1996, among the earliest cohort to join. The TPA is a living instrument rather than a fixed text: the consolidated version carries a status date, so the question to ask of any provision is not what the Act said but what it says as of the status date currently published.
WHAT TRANSFERS
Technical confidence, not market access. Switzerland sits outside the EU single market, so an EU marketing authorisation does not place a product on the Swiss market — the TPA governs that, and Swissmedic administers it. What its long PIC/S participation supports is mutual confidence in GMP inspection outcomes, which is a different currency from authorisation and is routinely confused with it. And a trap peculiar to this jurisdiction: the English text has no legal force. Fedlex states it plainly on the Act itself — English is not an official language of the Swiss Confederation and the translation is provided for information only. Anything that has to survive a regulatory challenge must be argued from the German, French or Italian text.
SR 812.21 is dated 15 December 2000 and has been amended repeatedly since. The consolidated text publishes a status date, and citing the Act without it is how a procedure ends up aligned to a superseded provision while looking correctly referenced.
The TPA covers medicinal products and medical devices in a single Act. Organisations that keep drug and device compliance in separate silos are working against the structure of the law they are being held to.
Article 2 brings narcotics into scope by reference to the Narcotics Act of 3 October 1951, and only insofar as they are used as therapeutic products. The controlled-substance obligations sit in that Act, not in the TPA.
Procedures, submissions and arguments that depend on exact wording have to be built on an official-language text. An English working translation is legitimate for understanding and illegitimate as authority.
The Federal Act on Medicinal Products and Medical Devices, known as the Therapeutic Products Act or TPA, classified as SR 812.21 and dated 15 December 2000. It covers medicinal products and medical devices together, and reaches narcotics under the Narcotics Act of 3 October 1951 where they are used as therapeutic products.
Not as authority. Fedlex states on the Act itself that English is not an official language of the Swiss Confederation and that the translation is provided for information purposes only and has no legal force. Use it to understand the requirement; argue from the German, French or Italian text.
No. Switzerland is outside the EU single market, and placing a therapeutic product on the Swiss market is governed by the TPA and administered by Swissmedic. Swissmedic has participated in PIC/S since February 1996, which supports mutual confidence in GMP inspection outcomes — a different thing from marketing authorisation.
Article 1 states the purpose: to protect human and animal health and to guarantee that only high quality, safe and effective therapeutic products are placed on the market. It also names protecting consumers against fraud and helping ensure a reliable, well-organised national supply.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Switzerland: requirements still arrive through the authorities below, and the edition in force is theirs to state.
Participation changes which evidence transfers, and which edition of a harmonized guide the local instrument is likely to pin.